Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estramustine in Breast Cancer Progression After Aromatase Inhibitor
NCT02866955Phase 2Completed
- Sponsor
- Institut de Cancérologie de Lorraine
- Start
- Jun 2011
- Primary completion
- Aug 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2 trial of estramustine in breast cancer (2 arms), sponsored by Institut de Cancérologie de Lorraine. Primary endpoint: Progression-free survival at 6 months. Started Jun 2011; status: completed.
02
Drugs
estramustine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02866955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866955.